TABLE 5

Any respiratory symptoms and use of asthma medication classified according to asthma treatment among subjects with persistent asthma, by asthma control classified according to Global Initiative for Asthma 2006 criteria [29] at follow-up

All#Controlled asthmaPartly controlled asthmaUncontrolled asthmap-value
Subjects n1821005824
Any respiratory symptoms at follow-up164 (90.1)88 (88.0)52 (89.7)24 (100.0)0.207
Treatment at follow-up
 No treatment36 (19.8)28 (28.0)8 (13.8)0 (0)
 SABA or LABA without ICS24 (13.2)16 (16.0)7 (12.1)1 (4.2)
 ICS with SABA or LABA periodically28 (15.4)17 (17.0)9 (15.5)2 (8.3)
 Low-dose ICS without LABA most days per week20 (11.0)9 (9.0)9 (15.5)2 (8.3)
 Low-dose ICS and LABA most days per week17 (9.3)7 (7.0)5 (8.6)5 (20.8)
 Medium/high-dose ICS and LABA most days per week57 (31.3)23 (23.0)20 (34.5)14 (58.3)0.004

Data are presented as n (%), unless otherwise stated. SABA: short-acting β2 agonist; LABA: long-acting β2 agonist; ICS: inhaled corticosteroid. #: n=182. Bold values indicate p<0.05.